{"id":"https://openalex.org/W7205727604","doi":null,"title":"Adverse events of DMT, 5-MeO-DMT, and ayahuasca according to the setting of administration: A systematic review","display_name":"Adverse events of DMT, 5-MeO-DMT, and ayahuasca according to the setting of administration: A systematic review","alternate_titles":[],"publication_year":2025,"publication_date":"2025-06-24","ids":{"openalex":"https://openalex.org/W7205727604"},"language":"en","primary_location":{"id":"pmh:oai:HAL:hal-05568685v1","doi":null,"is_oa":false,"landing_page_url":"https://hal.science/hal-05568685v1","pdf_url":null,"source":{"id":"https://openalex.org/S4306402512","display_name":"HAL","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I4405252976","host_organization_name":"Centre pour la Communication Scientifique Directe","host_organization_lineage":["https://openalex.org/I4405252976"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"Annual Meeting of French Society of Pharmacology and Therapeutics 2025, Jun 2025, Grenoble, France. Fundamental & Clinical Pharmacology, 39 (S1), pp.e70023","raw_type":"info:eu-repo/semantics/conferenceObject"},"parent_works":[],"lineage":["https://openalex.org/W7205727604"],"child_works_count":0,"type":"conference-paper","is_traditional":true,"indexed_in":[],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5049310595","display_name":"Romain Hacquet","orcid":"https://orcid.org/0009-0004-9232-7613","observed_orcids":["https://orcid.org/0009-0004-9232-7613"]},"institutions":[{"id":"https://openalex.org/I3019448017","display_name":"Centre Hospitalier Universitaire de Toulouse","ror":"https://ror.org/017h5q109","country_code":"FR","type":"healthcare","lineage":["https://openalex.org/I3019448017"]}],"countries":["FR"],"is_corresponding":false,"raw_author_name":"Hacquet, R.","raw_affiliation_strings":["Service d'Addictologie [CHU Toulouse] (Place du Docteur Baylac - TSA 40031 - 31059 Toulouse cedex 9 - France)"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Service d'Addictologie [CHU Toulouse] (Place du Docteur Baylac - TSA 40031 - 31059 Toulouse cedex 9 - France)","institution_ids":["https://openalex.org/I3019448017"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5056801799","display_name":"Bruno Pierre Guiard","orcid":"https://orcid.org/0000-0002-6873-9966","observed_orcids":["https://orcid.org/0000-0002-6873-9966"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"P. Guiard, B.","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5050870063","display_name":"Maryse Lapeyre\u2010Mestre","orcid":"https://orcid.org/0000-0002-5494-5873","observed_orcids":["https://orcid.org/0000-0002-5494-5873"]},"institutions":[{"id":"https://openalex.org/I3019448017","display_name":"Centre Hospitalier Universitaire de Toulouse","ror":"https://ror.org/017h5q109","country_code":"FR","type":"healthcare","lineage":["https://openalex.org/I3019448017"]}],"countries":["FR"],"is_corresponding":false,"raw_author_name":"Lapeyre-Mestre, M.","raw_affiliation_strings":["Service d'Addictologie [CHU Toulouse] (Place du Docteur Baylac - TSA 40031 - 31059 Toulouse cedex 9 - France)"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Service d'Addictologie [CHU Toulouse] (Place du Docteur Baylac - TSA 40031 - 31059 Toulouse cedex 9 - France)","institution_ids":["https://openalex.org/I3019448017"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5086216228","display_name":"\u00c9milie Jouanjus","orcid":"https://orcid.org/0000-0002-3510-2475","observed_orcids":["https://orcid.org/0000-0002-3510-2475"]},"institutions":[{"id":"https://openalex.org/I3019448017","display_name":"Centre Hospitalier Universitaire de Toulouse","ror":"https://ror.org/017h5q109","country_code":"FR","type":"healthcare","lineage":["https://openalex.org/I3019448017"]}],"countries":["FR"],"is_corresponding":false,"raw_author_name":"Jouanjus, E.","raw_affiliation_strings":["Service d'Addictologie [CHU Toulouse] (Place du Docteur Baylac - TSA 40031 - 31059 Toulouse cedex 9 - France)"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Service d'Addictologie [CHU Toulouse] (Place du Docteur Baylac - TSA 40031 - 31059 Toulouse cedex 9 - France)","institution_ids":["https://openalex.org/I3019448017"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5006807904","display_name":"Anne Roussin","orcid":"https://orcid.org/0000-0003-4541-3725","observed_orcids":["https://orcid.org/0000-0003-4541-3725"]},"institutions":[{"id":"https://openalex.org/I3019448017","display_name":"Centre Hospitalier Universitaire de Toulouse","ror":"https://ror.org/017h5q109","country_code":"FR","type":"healthcare","lineage":["https://openalex.org/I3019448017"]}],"countries":["FR"],"is_corresponding":false,"raw_author_name":"Roussin, A.","raw_affiliation_strings":["Service d'Addictologie [CHU Toulouse] (Place du Docteur Baylac - TSA 40031 - 31059 Toulouse cedex 9 - France)"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Service d'Addictologie [CHU Toulouse] (Place du Docteur Baylac - TSA 40031 - 31059 Toulouse cedex 9 - France)","institution_ids":["https://openalex.org/I3019448017"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":0.0,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":{"value":0.0,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":null,"biblio":{"volume":"39","issue":"S1","first_page":"e70023","last_page":null},"is_retracted":false,"is_pulled":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T12553","display_name":"Psychedelics and Drug Studies","score":1.0,"subfield":{"id":"https://openalex.org/subfields/3203","display_name":"Clinical Psychology"},"field":{"id":"https://openalex.org/fields/32","display_name":"Psychology"},"domain":{"id":"https://openalex.org/domains/2","display_name":"Social Sciences"}},"topics":[{"id":"https://openalex.org/T12553","display_name":"Psychedelics and Drug Studies","score":1.0,"subfield":{"id":"https://openalex.org/subfields/3203","display_name":"Clinical Psychology"},"field":{"id":"https://openalex.org/fields/32","display_name":"Psychology"},"domain":{"id":"https://openalex.org/domains/2","display_name":"Social Sciences"}},{"id":"https://openalex.org/T10800","display_name":"Forensic Toxicology and Drug Analysis","score":0.0,"subfield":{"id":"https://openalex.org/subfields/3005","display_name":"Toxicology"},"field":{"id":"https://openalex.org/fields/30","display_name":"Pharmacology, Toxicology and Pharmaceutics"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T12649","display_name":"Alkaloids: synthesis and pharmacology","score":0.0,"subfield":{"id":"https://openalex.org/subfields/3004","display_name":"Pharmacology"},"field":{"id":"https://openalex.org/fields/30","display_name":"Pharmacology, Toxicology and Pharmaceutics"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/n-n-dimethyltryptamine","display_name":"N,N-dimethyltryptamine","score":0.8799999952316284},{"id":"https://openalex.org/keywords/5-meo-dmt","display_name":"5-MeO-DMT","score":0.9570000171661377},{"id":"https://openalex.org/keywords/ayahuasca","display_name":"ayahuasca","score":1.0},{"id":"https://openalex.org/keywords/adverse-events","display_name":"adverse events","score":0.8429999947547913},{"id":"https://openalex.org/keywords/clinical-supervision","display_name":"clinical supervision","score":0.7630000114440918},{"id":"https://openalex.org/keywords/psychedelic-therapy","display_name":"psychedelic therapy","score":0.621999979019165},{"id":"https://openalex.org/keywords/psychiatric-adverse-effects","display_name":"psychiatric adverse effects","score":0.7770000100135803},{"id":"https://openalex.org/keywords/monoamine-oxidase-inhibitors","display_name":"monoamine oxidase inhibitors","score":0.7360000014305115}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.6171000003814697},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.6040999889373779},{"id":"https://openalex.org/C2777066114","wikidata":"https://www.wikidata.org/wiki/Q380436","display_name":"Ayahuasca","level":2,"score":0.5634999871253967},{"id":"https://openalex.org/C118552586","wikidata":"https://www.wikidata.org/wiki/Q7867","display_name":"Psychiatry","level":1,"score":0.4138999879360199},{"id":"https://openalex.org/C2779473830","wikidata":"https://www.wikidata.org/wiki/Q1540899","display_name":"MEDLINE","level":2,"score":0.29980000853538513},{"id":"https://openalex.org/C15744967","wikidata":"https://www.wikidata.org/wiki/Q9418","display_name":"Psychology","level":0,"score":0.28290000557899475},{"id":"https://openalex.org/C177713679","wikidata":"https://www.wikidata.org/wiki/Q679690","display_name":"Intensive care medicine","level":1,"score":0.2565000057220459},{"id":"https://openalex.org/C545542383","wikidata":"https://www.wikidata.org/wiki/Q2751242","display_name":"Medical emergency","level":1,"score":0.2551000118255615},{"id":"https://openalex.org/C2779134260","wikidata":"https://www.wikidata.org/wiki/Q12136","display_name":"Disease","level":2,"score":0.25380000472068787},{"id":"https://openalex.org/C2779662365","wikidata":"https://www.wikidata.org/wiki/Q5416694","display_name":"Event (particle physics)","level":2,"score":0.24549999833106995}],"mesh":[],"locations_count":1,"locations":[{"id":"pmh:oai:HAL:hal-05568685v1","doi":null,"is_oa":false,"landing_page_url":"https://hal.science/hal-05568685v1","pdf_url":null,"source":{"id":"https://openalex.org/S4306402512","display_name":"HAL","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I4405252976","host_organization_name":"Centre pour la Communication Scientifique Directe","host_organization_lineage":["https://openalex.org/I4405252976"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"Annual Meeting of French Society of Pharmacology and Therapeutics 2025, Jun 2025, Grenoble, France. Fundamental & Clinical Pharmacology, 39 (S1), pp.e70023","raw_type":"info:eu-repo/semantics/conferenceObject"}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","score":0.9922999739646912,"id":"https://metadata.un.org/sdg/3"}],"study_designs":[{"display_name":"Systematic Review","id":"https://openalex.org/study-designs/systematic-review"}],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W4293194637","https://openalex.org/W2589381868","https://openalex.org/W4393098915","https://openalex.org/W3094461574","https://openalex.org/W2156120803","https://openalex.org/W7214327777","https://openalex.org/W2036881116","https://openalex.org/W4404119411","https://openalex.org/W4390825728"],"abstract_inverted_index":{"Introduction:":[0],"The":[1,193],"set":[2],"(individual":[3],"dispositions)":[4],"and":[5,15,23,62,83,101,202,268],"setting":[6,47,264],"(environment)":[7],"during":[8],"psychedelics":[9,106],"administration":[10,263],"influence":[11],"their":[12,33],"psychotropic":[13],"effects":[14],"could":[16],"modulate":[17],"adverse":[18,49],"psychiatric":[19,198,223],"reactions.":[20],"N,N-Dimethyltryptamine":[21],"(DMT)":[22],"5-methoxy-N,N-dimethyltryptamine":[24],"(5-MeO-DMT)":[25],"are":[26],"gaining":[27],"therapeutic":[28],"interest,":[29],"particularly":[30],"due":[31,118,237],"to":[32,119,238,280,283],"short":[34],"half-life,":[35],"reducing":[36],"supervision":[37],"time":[38],"in":[39,71,96,213,227,270,288],"clinical":[40,80,102,183,186,228,271],"context.":[41,290],"However,":[42,244],"the":[43,46,110,120,131,135,151,167,182,239,251,258,262],"role":[44],"of":[45,74,93,122,134,141,195,208,222,234,241,261,265],"on":[48],"events":[50],"(AEs)":[51],"remains":[52],"underexplored.":[53],"This":[54,254],"study":[55],"compared":[56],"AEs":[57,94,143,164,196,206,224],"reported":[58,95,123,145,209,249],"for":[59,107],"DMT,":[60,266],"5-MeO-DMT,":[61,267],"ayahuasca":[63,269],"(decoction":[64],"containing":[65],"DMT":[66],"with":[67,162,217,230],"monoamine":[68],"oxidase":[69],"inhibitors)":[70],"different":[72],"contexts":[73],"administration:":[75],"unsupervised,":[76],"nonclinical":[77,168,214],"supervised,":[78],"or":[79,127],"supervised":[81,169],"settings.Material":[82],"methods:":[84],"Following":[85],"PRISMA":[86],"recommendations,":[87],"we":[88],"performed":[89],"a":[90,231],"systematic":[91],"review":[92,255],"case":[97,157],"reports,":[98],"observational":[99,174],"studies,":[100,113],"trials":[103,187],"involving":[104,146],"these":[105],"1990\u20132022.Results:":[108],"Of":[109],"231":[111],"eligible":[112],"170":[114],"were":[115,144,197],"excluded,":[116],"mainly":[117],"absence":[121],"AEs.":[124],"High":[125],"variability":[126],"insufficient":[128],"description":[129,260],"regarding":[130],"precise":[132,259],"conditions":[133],"settings":[136],"was":[137,225,247],"observed.":[138],"A":[139,219],"total":[140],"8053":[142],"15":[147],"745":[148],"individuals.":[149],"In":[150,166,181],"unsupervised":[152],"setting,":[153,170,184],"22":[154,171],"articles":[155,172],"(mainly":[156,173],"reports)":[158],"involved":[159],"7701":[160],"individuals":[161,178,190],"7434":[163],"reported.":[165],"studies)":[175],"covered":[176],"7792":[177],"(190":[179],"AEs).":[180,192],"18":[185],"included":[188],"252":[189],"(429":[191],"majority":[194],"(48.3%),":[199],"neurologic":[200],"(15.0%),":[201],"cardiovascular":[203],"(6.3%).":[204],"Serious":[205],"(1.1%":[207],"AEs)":[210],"predominantly":[211],"occurred":[212],"settings,":[215],"mostly":[216],"ayahuasca.":[218],"lower":[220,232],"rate":[221],"observed":[226,287],"context,":[229],"incidence":[233],"psychotic":[235],"episodes":[236],"exclusion":[240],"at-risk":[242],"patients.":[243],"transient":[245,285],"anxiety":[246,286],"frequently":[248,274],"across":[250],"three":[252],"settings.Discussion/conclusion:":[253],"evidenced":[256],"that":[257],"studies":[272],"is":[273],"lacking,":[275],"whereas":[276],"it":[277],"should":[278],"help":[279],"elaborate":[281],"recommendations":[282],"decrease":[284],"this":[289]},"cited_by_api_url":"https://api.openalex.org/works?filter=cites:W7205727604","counts_by_year":[],"updated_date":"2026-11-14T11:04:58.165337","created_date":"2026-09-02T00:00:00"}
